If you have been diagnosed with major depressive disorder and have tried at least two antidepressants without adequate relief, you may qualify for ketamine-based treatment. Roughly 30% of people with major depression fall into this treatment-resistant category, and for them, ketamine represents one of the most significant breakthroughs in psychiatric medicine in decades. A single low-dose infusion can begin alleviating depressive symptoms within hours — not the weeks or months that traditional antidepressants require — with effects lasting approximately one week. For someone who has spent years cycling through medications that don’t work, that kind of timeline can feel like a lifeline.
As for what it actually feels like, most patients describe a dissociative state lasting 30 to 45 minutes: a sensation of floating, warmth, or separation from their body that many find strange but not unpleasant. People with chronic depression frequently say it feels as though a heavy blanket has been temporarily lifted. The side effects — dizziness, nausea, mild sedation — generally resolve within two hours. This article covers who specifically qualifies, the difference between IV ketamine and the FDA-approved nasal spray Spravato, what a treatment session involves from start to finish, how much it costs, and what recent research from 2025 and 2026 tells us about how well it actually works compared to older protocols.
Table of Contents
- Who Actually Qualifies for Ketamine Treatment for Depression?
- Spravato vs. IV Ketamine — What Is the Difference and Which Works Better?
- What a Ketamine Session Actually Feels Like, From Start to Finish
- How Much Does Ketamine Treatment Cost, and Will Insurance Cover It?
- Risks, Limitations, and Who Should Not Use Ketamine
- New Research Is Changing How Ketamine Is Used
- Where Ketamine Treatment Is Headed
- Conclusion
- Frequently Asked Questions
Who Actually Qualifies for Ketamine Treatment for Depression?
The primary qualification is treatment-resistant depression, defined clinically as a failure to respond adequately to at least two different antidepressant medications taken at appropriate doses for sufficient duration. this is not a casual threshold. Your psychiatrist needs to document that you have genuinely tried and failed conventional options — not just that you felt a medication “wasn’t working” after two weeks. For the FDA-approved nasal spray Spravato (esketamine), there is a second qualifying pathway: adults with major depressive disorder who are experiencing acute suicidal ideation or behavior. This expanded indication was approved in August 2020 and has provided a critical option for patients in psychiatric crisis. There are important exclusions.
Spravato is approved for adults 18 and older, with an FDA black box warning advising against use in patients under 24 due to increased risk of suicidal thoughts — the same warning that applies to traditional antidepressants in younger adults. Patients with uncontrolled hypertension, aneurysmal vascular disease, or a history of intracerebral hemorrhage are generally excluded because ketamine can raise blood pressure. If you have a history of substance abuse, particularly with dissociative drugs, many clinicians will exercise additional caution or decline treatment. This is worth being upfront about during your screening — providers are evaluating risk, not making moral judgments. For those considering off-label IV ketamine rather than Spravato, the qualifying criteria are often more flexible since it falls outside the FDA’s formal indication framework. Individual clinics set their own protocols, and some will treat patients who have failed just one antidepressant or who have severe anxiety disorders. However, the lack of standardization means the burden falls on you to find a reputable provider who conducts proper psychiatric evaluations before starting treatment.
Spravato vs. IV Ketamine — What Is the Difference and Which Works Better?
There are two main delivery methods, and they are not interchangeable. Spravato is esketamine — the S-enantiomer of ketamine — delivered as a nasal spray. It was FDA-approved in March 2019 for treatment-resistant depression. In a significant update in January 2025, the FDA approved Spravato as the first standalone treatment for TRD, meaning it no longer requires co-administration with an oral antidepressant. IV ketamine, by contrast, uses the racemic form (both S and R enantiomers) and remains FDA-approved only as an anesthetic. Its use for depression is entirely off-label, though supported by decades of clinical evidence. A comparative study from Mass General Brigham involving 153 patients found that IV ketamine produced a 49.22% reduction in depression scores compared to 39.55% for intranasal esketamine, with IV ketamine also delivering faster initial improvements. However, this does not automatically make IV ketamine the better choice for every patient.
Spravato comes with an established insurance reimbursement pathway — Medicare Part B generally covers it — and the FDA’s REMS program ensures standardized monitoring. IV ketamine is almost always self-pay, and clinic quality varies widely. The practical tradeoff is this: if your insurance covers Spravato and you meet the FDA criteria, it is the more accessible and regulated option. If you have tried Spravato without sufficient benefit, or if you are paying out of pocket regardless, IV ketamine may offer a stronger clinical response. Neither option is something you administer at home. Spravato must be given in a certified healthcare setting with at least two hours of post-dose monitoring. IV infusions similarly require clinical supervision. Be deeply skeptical of any provider offering unsupervised take-home ketamine without robust psychiatric oversight.
What a Ketamine Session Actually Feels Like, From Start to Finish
The dissociation is the part people ask about most, and it deserves an honest description. Within 10 to 15 minutes of an IV infusion beginning, most patients notice a shift in perception. The room may seem slightly unreal. Sounds might feel distant or oddly textured. Many describe a sense of floating or lightness, as though gravity has loosened its grip. Some experience vivid internal imagery — not hallucinations in the clinical sense, but a kind of waking dreaminess. Others simply feel warm, heavy, and deeply relaxed. The dissociative peak typically lasts 30 to 45 minutes and then gradually fades. Patients with chronic, severe depression often describe the experience in emotional rather than perceptual terms.
The persistent interior monologue of hopelessness and self-criticism goes quiet. Some people cry — not from distress, but from what they describe as relief at feeling something other than numbness or despair for the first time in months or years. This is not universal. Some patients find the dissociation uncomfortable or anxiety-provoking, particularly during their first session. Nausea is common, and clinicians often administer an anti-nausea medication beforehand. Elevated blood pressure, dizziness, blurred vision, and headache can occur, though these side effects are generally mild and resolve within two hours according to NIH data. What matters most to people considering this treatment is this: the experience itself is temporary, but the antidepressant effect can outlast it by days. A single infusion can produce meaningful symptom reduction within 24 to 48 hours. The strange 45 minutes in the chair is not the point — the point is the week that follows, during which many patients report their first sustained period of genuine mood improvement in years.
How Much Does Ketamine Treatment Cost, and Will Insurance Cover It?
Cost is the barrier that stops most eligible patients, and the landscape is genuinely complicated. IV ketamine infusions run between $400 and $800 per session nationally, with some clinics in less expensive regions charging as low as $350 and premium metro clinics going as high as $1,400. The standard induction protocol involves six to eight infusions over two to three weeks, putting the initial cost at $2,400 to $6,400. After that, maintenance sessions are typically needed monthly or bi-monthly at $400 to $800 each. Nearly all IV ketamine treatment is self-pay because the off-label status means most insurers will not cover it. Spravato presents a different financial picture.
The list price is $590 per 56 mg dose or $885 per 84 mg dose, and the treatment protocol involves twice-weekly sessions during the first month, weekly sessions during the second month, and then weekly or every-other-week sessions thereafter. However, because Spravato is FDA-approved, insurance coverage is far more common. Most eligible patients with commercial insurance pay under $500 per month out of pocket, and Medicare Part B generally covers the drug. Janssen, the manufacturer, also offers a savings program for commercially insured patients. The comparison is not as straightforward as “Spravato is cheaper because insurance covers it.” If your insurance denies Spravato coverage — which happens — you are looking at sticker prices that exceed IV ketamine per session. And if you respond better to IV ketamine based on the clinical evidence showing stronger depression score reductions, paying more for a less effective treatment is a poor bargain. Talk to your provider and your insurer simultaneously before committing to either pathway.
Risks, Limitations, and Who Should Not Use Ketamine
Ketamine is not a cure for depression. It is a powerful intervention that can break through treatment resistance, but its effects are temporary without ongoing maintenance. A single infusion’s antidepressant benefit lasts approximately one week. Even with repeated infusions, the effects diminish over time if treatment stops entirely. This is not a failure of the drug — it is the nature of the condition it treats. Treatment-resistant depression is, by definition, difficult to manage long-term. The abuse potential is real and must be acknowledged honestly. Ketamine is a Schedule III controlled substance with known dissociative and euphoric properties.
While clinical protocols use sub-anesthetic doses that are far lower than recreational use, the subjective pleasantness of the experience can create psychological dependence in vulnerable patients. Reputable providers screen for substance use history and monitor patients for signs of misuse. The REMS program for Spravato exists specifically because of these concerns — the requirement for in-clinic administration and two-hour monitoring is a safeguard, not an inconvenience. There are also populations for whom the risks outweigh the benefits. Patients with uncontrolled high blood pressure face genuine cardiovascular danger from ketamine’s hypertensive effects. Those with a history of psychosis may experience worsening symptoms. Pregnant patients should not use ketamine. And for older adults — a population particularly relevant to brain health — the blood pressure concerns are amplified, and the dissociative effects can be more disorienting. If you are over 65, your provider should be conducting careful cardiovascular screening and starting at the lowest effective dose.
New Research Is Changing How Ketamine Is Used
A March 2026 brain imaging study from Yokohama City University, published in Molecular Psychiatry, revealed how ketamine reshapes NMDA receptor activity in specific brain regions tied to mood and reward processing. This research is significant because it moves beyond the simple narrative that “ketamine works fast” and begins explaining the precise neural mechanisms — knowledge that could eventually lead to more targeted treatments with fewer side effects. Separately, the KARMA-Dep 2 trial published in JAMA Psychiatry demonstrated that serial ketamine infusions as adjunctive therapy to inpatient psychiatric care significantly reduced depression severity, supporting the case for integrating ketamine into hospital settings rather than limiting it to outpatient clinics.
Perhaps the most practically relevant recent finding comes from McGill University’s “Montreal Model,” which combines ketamine infusions with psychotherapy and a supportive treatment environment. This integrated approach extended the antidepressant benefits to at least eight weeks — a dramatic improvement over the roughly one-week duration seen with standard ketamine-only protocols. The implication is clear: ketamine works best not as a standalone drug but as a catalyst that opens a window of neuroplasticity during which therapy can take deeper root.
Where Ketamine Treatment Is Headed
The January 2025 FDA decision allowing Spravato as a standalone treatment — without requiring a co-prescribed oral antidepressant — signals a broader shift in how regulators view ketamine-derived therapies. It is no longer positioned as a last-resort add-on but as a legitimate primary treatment for people whose depression has not responded to conventional options. Combined with research like the Montreal Model showing that pairing ketamine with psychotherapy dramatically extends its benefits, the trajectory points toward more integrated, protocol-driven treatment programs rather than the current patchwork of independent infusion clinics.
For the brain health community, the relevance extends beyond depression alone. The neuroplasticity mechanisms revealed by the Yokohama City University study have implications for neurodegenerative conditions, cognitive decline, and the intersection of depression with dementia — a comorbidity that affects millions of older adults and is notoriously difficult to treat with conventional antidepressants. Ketamine is not a dementia treatment, but understanding how it rapidly reshapes neural circuitry may eventually inform entirely new approaches to preserving cognitive function under the pressure of both mood disorders and neurodegeneration.
Conclusion
Ketamine-based treatment for depression is neither a miracle drug nor a fringe therapy. It is an evidence-backed option for adults with treatment-resistant depression — those who have tried at least two antidepressants without adequate relief — and for those with major depressive disorder accompanied by acute suicidal ideation. The FDA-approved nasal spray Spravato offers a regulated, increasingly insurance-covered pathway, while off-label IV ketamine provides potentially stronger symptom reduction at higher out-of-pocket cost. Both require clinical supervision, both carry real side effects that resolve within hours, and both produce rapid antidepressant responses that traditional medications cannot match.
If you think you may qualify, the next step is a conversation with your psychiatrist — not a Google search for the nearest ketamine clinic. A proper evaluation should include a review of your medication history, cardiovascular health, and substance use risk factors. Ask specifically whether Spravato or IV ketamine is more appropriate for your situation, and get clarity on insurance coverage before your first appointment. For people who have spent years in the grip of depression that refuses to respond to conventional treatment, ketamine represents a genuinely different mechanism of action and a realistic chance at relief. That chance deserves to be pursued carefully, with the right provider, and with honest expectations about what the treatment can and cannot do.
Frequently Asked Questions
How quickly does ketamine work for depression?
Symptom improvement can begin within 24 to 48 hours of the first dose — dramatically faster than traditional antidepressants, which typically take four to six weeks. However, a single infusion’s effects last only about one week, so repeated treatments are necessary for sustained benefit.
Can I drive myself home after a ketamine treatment session?
No. Both IV ketamine and Spravato cause dissociation, dizziness, and sedation. Spravato’s REMS program requires a minimum two-hour monitoring period before discharge, and you must arrange transportation home. Most IV ketamine clinics have similar requirements.
Is ketamine therapy covered by insurance?
Spravato (esketamine nasal spray) is increasingly covered by commercial insurance and Medicare Part B, with most eligible patients paying under $500 per month out of pocket. IV ketamine is almost entirely self-pay because its use for depression is off-label. Expect to pay $2,400 to $6,400 for the initial six to eight infusion series.
What disqualifies someone from ketamine treatment?
Uncontrolled hypertension, aneurysmal vascular disease, history of intracerebral hemorrhage, active psychosis, and pregnancy are common exclusions. Patients under 18 are not eligible for Spravato, and those under 24 carry an FDA black box warning for increased suicidal ideation risk.
Does ketamine cure depression permanently?
No. Ketamine provides rapid but temporary relief. Without maintenance infusions — typically monthly or bi-monthly — symptoms generally return. Research from McGill University’s Montreal Model suggests that combining ketamine with psychotherapy can extend benefits to at least eight weeks, but ongoing treatment is still expected.
Is at-home ketamine treatment safe?
The FDA-approved pathway (Spravato) explicitly requires in-clinic administration with monitoring. While some providers prescribe oral or sublingual ketamine for at-home use, this practice lacks FDA endorsement for depression and carries higher risks of misuse, dosing errors, and inadequate monitoring. Proceed with extreme caution and only under close psychiatric supervision.
